Protara Therapeutics, Inc. TARA
2.43 USD -0.08 (-3.19%)
At closeNov 10, 2026, 4:01 PM EST
2.43 0.00 0.00%
After hours · Nov 10, 4:01 PM ET
2.33 Day range 2.51
2.13 52-week range 7.56
- YTD
- -54.41%
- 1 year
- -46.36%
News
benzinga.com Protara Therapeutics Q3 EPS $(0.35) Beats $(0.37) Estimate Protara Therapeutics (NASDAQ:TARA) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0.37) by 5.41 percent. This is a 12.9 percent decrease over losses of…
globenewswire.com Protara Therapeutics Announces Third Quarter 2026 Financial Results and Provides a Business Update Expect to complete enrollment of the BCG-Unresponsive registrational cohort of the ADVANCED-2 trial of TARA-002 in NMIBC by year-end 2026
globenewswire.com Protara Therapeutics Completes Enrollment of the Phase 2b Open-Label Dose Confirmation Phase of the THRIVE-3 Registrational Trial of IV Choline Chloride in Patients on Parenteral Support Company remains on track to report interim results from Phase 2b cohort in 4Q 2026 NEW YORK, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage…
globenewswire.com Protara Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases,…
defenseworld.net Bank of America Corp DE Buys 430,014 Shares of Protara Therapeutics, Inc. $TARA Bank of America Corp DE grew its stake in shares of Protara Therapeutics, Inc. (NASDAQ: TARA) by 86.7% during the first quarter, according to the company in its most recent disclosure with the…
benzinga.com Protara Therapeutics Q2 EPS $(0.36) Misses $(0.33) Estimate Protara Therapeutics (NASDAQ:TARA) reported quarterly losses of $(0.36) per share which missed the analyst consensus estimate of $(0.33) by 9.09 percent. This is a 2.86 percent decrease over losses…
seekingalpha.com Protara Therapeutics: Orphan Drug Indications Drive A Heavily Undervalued Pipeline Protara Therapeutics is rated Buy, with a risk-adjusted fair value of $9.96 per share versus the current ~$4 price. TARA-002 targets NMIBC and Lymphatic Malformations; orphan drug indications offer…
defenseworld.net Protara Therapeutics, Inc. (NASDAQ:TARA) Receives Average Rating of “Moderate Buy” from Brokerages Shares of Protara Therapeutics, Inc. (NASDAQ: TARA - Get Free Report) have received an average rating of "Moderate Buy" from the eight research firms that are presently covering the company,…
zacks.com What Makes Protara Therapeutics (TARA) a New Buy Stock Protara Therapeutics (TARA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
prnewswire.com ROYAL CARIBBEAN GROUP APPOINTS TARA BUNCH TO BOARD OF DIRECTORS MIAMI, July 20, 2026 /PRNewswire/ -- Royal Caribbean Group (NYSE: RCL) today announced the appointment of Tara Bunch, former Senior Vice President and Global Head of Operations at Airbnb, to its…
businesswire.com Tradeweb Launches TARA, an AI-Powered Research Assistant for Institutional Credit Trading NEW YORK--(BUSINESS WIRE)--Tradeweb Markets Inc. (Nasdaq: TW), a global leader in electronic trading across asset classes, today announced the launch of TARA (Tradeweb AI Research Assistant), a…
benzinga.com Protara Therapeutics Enters $100M At-the-Market Equity Sales Agreement With TD Cowen $100,000,000Common StockWe have entered into a sales agreement with TD Securities (USA) LLC, or TD Cowen, dated May 13, 2026, or the Sales Agreement, relating to the sale of shares of our common…
benzinga.com Oppenheimer Maintains Outperform on Protara Therapeutics, Raises Price Target to $28 Oppenheimer analyst Leland Gershell maintains Protara Therapeutics (NASDAQ:TARA) with a Outperform and raises the price target from $25 to $28.
globenewswire.com Protara Therapeutics to Present at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage biotechnology company committed to advancing transformative therapies for the treatment of…
seekingalpha.com Protara Therapeutics, Inc. (TARA) Discusses Interim Safety and Durability Data From STARBORN-1 Trial of TARA-002 in Lymphatic Malformations Transcript Protara Therapeutics, Inc. (TARA) Discusses Interim Safety and Durability Data From STARBORN-1 Trial of TARA-002 in Lymphatic Malformations Transcript
benzinga.com Protara Therapeutics To Host Investor Webinar On TARA-002 Program And Treatment Landscape For Lymphatic Malformations On May 19, 2026 Event will provide an overview of Lymphatic Malformations, the treatment landscape and the TARA-002 clinical programNEW YORK, May 18, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc.…
globenewswire.com Protara Therapeutics to Host Virtual Investor Webinar to Discuss TARA-002 for Lymphatic Malformations on Tuesday, May 19, 2026 Event will provide an overview of Lymphatic Malformations, the treatment landscape and the TARA-002 clinical program NEW YORK, May 18, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq:…
benzinga.com Protara Therapeutics Reports 55% Complete Response Rate In Bladder Cancer Study Protara Therapeutics Inc. (NASDAQ:TARA) reported updated 12-month Phase 2 data for TARA-002 in patients with Bacillus Calmette-Guérin (BCG)-naïve non-muscle invasive bladder cancer (NMIBC),…
benzinga.com Protara Therapeutics Reports 55% Complete Response Rate In Bladder Cancer Study Protara reports updated Phase 2 data showing durable responses and favorable safety for TARA-002 in bladder cancer patients.- benzinga.com Protara Therapeutics Reports TARA-002 Achieves 72% Complete Response Rate In BCG-Naïve NMIBC Patients With Durable 55% Rate At 12 Months TARA-002 demonstrates 72% complete response rate at any time, 67% complete response rate at the 6-month landmark and 55% complete response rate at the 12-month landmark in BCG-Naïve
globenewswire.com Protara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses in the Fully Enrolled BCG-Naïve Cohort of the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in NMIBC TARA-002 demonstrates 72% complete response rate at any time, 67% complete response rate at the 6-month landmark and 55% complete response rate at the 12-month landmark in BCG-Naïve patients- benzinga.com JP Morgan Maintains Overweight on Protara Therapeutics, Lowers Price Target to $26 JP Morgan analyst Brian Cheng maintains Protara Therapeutics (NASDAQ:TARA) with a Overweight and lowers the price target from $27 to $26.
benzinga.com Protara Therapeutics Q1 EPS $(0.31) Beats $(0.37) Estimate Protara Therapeutics (NASDAQ:TARA) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate of $(0.37) by 16.22 percent. This is a 6.9 percent decrease over losses of…
globenewswire.com Protara Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update The Company intends to submit a Biologics License Application (BLA) for TARA-002 in Lymphatic Malformations (LMs) in 2H 2027 Hosting virtual investor webinar discussing LMs program with key opinion…- benzinga.com HC Wainwright & Co. Maintains Buy on Protara Therapeutics, Raises Price Target to $27 HC Wainwright & Co. analyst Andrew S. Fein maintains Protara Therapeutics (NASDAQ:TARA) with a Buy and raises the price target from $23 to $27.
benzinga.com Protara Therapeutics To Demonstrate Interim Data From Cohort A Of Its Current Phase 2 Open-Label ADVANCED-2 Study Of TARA-002 In Participants With BCG-Naïve Non-Muscle Invasive Bladder Cancer At American Urological Association 2026 Annual Meeting Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage biotechnology company developing transformative therapies for the treatment of cancer and rare diseases, today announced that updated,…
globenewswire.com Protara Therapeutics to Present Updated, Interim 12-Month Data from the Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the American Urological Association Annual Meeting NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage biotechnology company developing transformative therapies for the treatment of cancer and rare…
defenseworld.net Protara Therapeutics, Inc. (NASDAQ:TARA) Sees Significant Increase in Short Interest Protara Therapeutics, Inc. (NASDAQ: TARA - Get Free Report) was the recipient of a large increase in short interest in the month of February. As of February 27th, there was short interest totaling…
benzinga.com Protara Therapeutics Q4 EPS $(0.37) Misses $(0.33) Estimate Protara Therapeutics (NASDAQ:TARA) reported quarterly losses of $(0.37) per share which missed the analyst consensus estimate of $(0.33) by 13.85 percent. This is a 22.92 percent increase over losses…
globenewswire.com Protara Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update Reported interim data from ADVANCED-2 trial in non-muscle invasive bladder cancer (NMIBC); TARA-002 demonstrated 68% complete response rate at six months in BCG-Unresponsive patients Company expects…- benzinga.com JP Morgan Initiates Coverage On Protara Therapeutics with Overweight Rating, Announces Price Target of $27 JP Morgan analyst Brian Cheng initiates coverage on Protara Therapeutics (NASDAQ:TARA) with a Overweight rating and announces Price Target of $27.
defenseworld.net Protara Therapeutics Highlights TARA-002 NMIBC Data, FDA Plans for Lymphatic Malformations at Oppenheimer Conf Protara Therapeutics (NASDAQ: TARA) executives outlined progress across the company's two clinical-stage programs during a fireside chat at Oppenheimer's 36th Annual Healthcare Life Sciences…
seekingalpha.com Protara Therapeutics, Inc. (TARA) Discusses Interim Phase II Results for TARA-002 in Non-Muscle Invasive Bladder Cancer Transcript Protara Therapeutics, Inc. (TARA) Discusses Interim Phase II Results for TARA-002 in Non-Muscle Invasive Bladder Cancer Transcript
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session 
benzinga.com Ultra Clean Posts Downbeat Earnings, Joins Paymentus, Whirlpool And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session 
benzinga.com Protara's Experimental Bladder Cancer Drug Shows Encouraging Results Protara Therapeutics (TARA) shares down after release of interim results for TARA-002 treatment of Non-Muscle Invasive Bladder Cancer.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session 
benzinga.com Why Keysight Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket - benzinga.com Protara Therapeutics Announces Updated Interim Results From Ongoing Phase 2 Open-Label ADVANCED-2 Trial Assessing Intravesical TARA-002 In Patients With High-Risk NMIBC Favorable safety and tolerability profile with no Grade 3 or greater treatment-related adverse eventsCompany expects to complete enrollment of the BCG-Unresponsive cohort of the ADVANCED-2 trial in…
- benzinga.com HC Wainwright & Co. Reiterates Buy on Protara Therapeutics, Maintains $23 Price Target HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Protara Therapeutics (NASDAQ:TARA) with a Buy and maintains $23 price target.
benzinga.com Protara Therapeutics To Feature Interim Data From Cohort Of BCG-Unresponsive NMIBC Patients In Ongoing Phase 2 ADVANCED-2 Trial Of TARA-002 At Upcoming ASCO GU Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that updated interim data from…- benzinga.com Protara Therapeutics Enters 2026 With Advancing TARA-002 Programs, Registrational Trials And Extended Cash Runway Into 2028 On track to report interim results from approximately 25 six-month evaluable BCG-Unresponsive patients in ADVANCED-2 trial in Q1 2026Received Breakthrough Therapy and Fast Track designations for…
- benzinga.com Piper Sandler Initiates Coverage On Protara Therapeutics with Overweight Rating, Announces Price Target of $24 Piper Sandler analyst Kelsey Goodwin initiates coverage on Protara Therapeutics (NASDAQ:TARA) with a Overweight rating and announces Price Target of $24.
- benzinga.com Protara Therapeutics Announces Patient Dosing In Phase 3 Registrational THRIVE-3 Clinical Trial Evaluating IV Choline Chloride In Patients Receiving Long-Term Parenteral Support Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that patient dosing is now…
- benzinga.com Protara Therapeutics' TARA-002 Gets FDA's Breakthrough Therapy, Fast Track Designations To Treat Macrocystic, Mixed Cystic Lymphatic Malformations Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that the U.S. Food and Drug…
- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session 
benzinga.com Why Ulta Beauty Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket - benzinga.com Protara Therapeutics Announces Proposed $75M Public Offering To Fund Clinical Development Of TARA-002 And Pipeline Programs Protara Therapeutics, Inc. (NASDAQ:TARA) ("Protara"), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that it has commenced…
- benzinga.com HC Wainwright & Co. Reiterates Buy on Protara Therapeutics, Maintains $23 Price Target HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Protara Therapeutics (NASDAQ:TARA) with a Buy and maintains $23 price target.